Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3139-3152

  Begemann, Martin ^a,c   Kashimawo, Sharafadeen A ^a   Lunn, Ruth M ^a   Delohery, Thomas ^b   Choi, Yu Jeong A ^a   Kim, Susan ^a   Heitjan, Daniel F ^a   Santella, Regina M ^a   Schiff, Peter B ^a   Bruce, Jeffrey N ^a   Weinstein, I Bernard ^a  

^a Department of Orthopaedic Surgery   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bcl 2; Chemotherapy; p53; PKC

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; CALPHOSTIN C; DNA FRAGMENT; HISTONE H1; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN P53;

APOPTOSIS; ARTICLE; CLONOGENESIS; DNA BINDING; ENZYME INHIBITION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MISSENSE MUTATION; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; CDC2 PROTEIN KINASE; CELL DIVISION; DNA FRAGMENTATION; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, P53; GLIOBLASTOMA; HUMANS; INDOLES; NAPHTHALENES; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0031762618     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Salcman M, Scholtz H, Kaplan RS and Kulik S: Long-term Survival in patients with malignant astrocytoma. Neurosurgery 34: 213-220, 1994.
2. Salcman M: Survival in glioblastoma: historical perspective. Neurosurgery 7: 435-439, 1980.
3. Chandler KL, Prados MD, Malec M and Wilson CB: Long term survival in patients with glioblastoma multiforme. Neurosurgery 32: 716-720, 1993.
4. Petersdorf SH and Livingston RB: High dose chemotherapy for the treatment of malignant brain tumors. J Neuro-Oncol 20: 155-163, 1994.
5. Begemann M, Kashimawo SA, Choi YJA, Kim S, Christiansen KM, Duigou G, Mueller M, Schieren I, Ghosh S, Fabbro D, Lampen NM, Schiff PB, Bruce JN and Weinstein IB: Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C and by a phorbol ester tumor promoter. Clin Cancer Res 2: 1017-1030, 1996.
6. Nishizuka Y: The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308: 693-698, 1984.
7. Nishizuka Y: Studies and perspectives of protein kinase C. Science 233: 305-312, 1986.
8. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334: 661-665, 1988.
9. Weinstein IB, Borner CB, Krauss RS, O'Driscoll K, Choi PM, Moritomi M, Hoshina S, Hsieh L-L, Tchou-Wong K-M, Nichols-Guadagno S, Ueffing M and Guillem J: Pleiotropic effects of protein kinase C and the concept of carcinogenesis as a progressive disorder in signal transduction. In: J Brugge, T Curran, E Harlow and F McCormick (eds.), Origins of Human Cancer: A Comprehensive Review, NY: Cold Spring Harbor Laboratory, 1991.
10. Harris W, Hill CH, Lewis EJ, Nixon JS and Wilkinson SE: Protein kinase C inhibitors. Drugs Fut 18: 727-735, 1993.
11. Marte BM, Meyer T, Stabel S, Standke GJR, Jaken S, Fabbro D and Hynes NE: Protein kinase C and mammary cell differentiation: Involvement of protein kinase Ca in the induction of ß-casein expression. Cell Growth Diff 5: 239-247, 1994.
12. Birchall AM, Bishop J, Bradshaw D, Cline A, Coffey J, Elliott LH, Gibson VM, Greenham A, Hallam TJ, Harrris W, Hill CH, Hutchings A, Lamont-AG, Laston G, Lewis EJ, Maw A, Nixon JS, Pole D, Wadsworth J and Wilkinson SE: Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation. J Pharmacol Exp Therap 268: 922-929, 1994.
13. Bit RA, Davis PD, Elliott LH, Harris W, Hill CH, Keech E, Kumar H, Lawton G, Maw A, Nixon JS, Vesey DR, Wadsworth J and Wilkinson SE: Inhibitors of Protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. J Med Chem 36: 21-29, 1993.
14. Kobayashi E, Nakano H, Morimoto M and Tamaoki T: Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Comm 159: 548-553, 1989.
15. Kobayashi E, Katsuhiko A, Nakano H, Iida T, Ohno H, Morimoto M and Tamaoki T: Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C. J Antibiotics 42: 1470-1481, 1989.
16. Bruns RF, Miller FD, Merriman RL, Howbert JJ, Heath WF, Kobayashi E, Takahashi I, Tamaoki T and Nakano H: Inhibition of protein kinase C by calphostin C is light-dependent. Biochem Biophys Res Comm 176: 288-293, 1991.
17. Rotenberg SA, Huang MH, Zhu J, Su L and Riedel H: Deletion analysis of protein kinase C inactivation by calphostin C. Molecular Carcinogenesis 12: 42-49, 1995.
18. Korsmeyer SJ: Regulators of cell death. TIG 11: 101-103, 1995.
19. Strasser A, Harris AW, Jacks T and Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by bcl-2. Cell 79: 329-339, 1994.
20. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
21. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
22. Ramqvist T, Magnusson KP, Wang Y, Szekely L, Klein G and Wiman KG: Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 8: 1495-1500, 1993.
23. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KTJ, Levin VA and Yung WKA: Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56: 694-699, 1996.
24. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
25. King RW, Jackson PK and Kirschner MW: Mitosis in transition. Cell 79: 563-571, 1994.
26. Hunter T and Pines J: Cyclins and Cancer II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
27. van den Heuvel S and Harlow E: Distinct roles for cyclin-dependent kinases in cell-cycle control. Science 262: 2050-2054, 1993.
28. Hall E: Radiobiology for the radiologist. 4th ed. JB Lippincott Company, Philadelphia, 1994.
29. Li X, Traganos F, Melamed MR and Darzynkiewicz Z: Single-step procedure for labeling DNA strand breaks with fluorescein- or BODIPY-conjugated deoxynucleotides: detection of apoptosis and bromodeoxyuridine incorporation. Cytometry 20: 172-180, 1995.
30. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos FA: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
31. Van der Ploeg LHT, Gottesdiener KM, Korman SH, Weiden M and Le Blancq S: Protozoan Genomes - Karyotype analysis, chromosome structure, and chromosome specific libraries. In: M Burmeister and L Ulanovsky (eds.), Methods in Molecular Biology, Vol. 12: Pulsed-Field Electrophoresis, pp. 203-223, Totowa: The Humana Press, Inc. 1992.
32. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM and Dalla-Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U.S.A. 88: 5413-5417, 1991.
33. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ and Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428, 1991.
34. Buetow KH, Sheffield VC, Zhu M, Zhou T, Shen F-M, Hino O, Smith M, McMahon BJ, Lanier AP, London WT, Redeker AG and Govindarajan S: Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci U.S.A. 89: 9622-9626, 1992.
35. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR and Reed SI: A novel inhibitor of cyclin-cdk activity detected in transforming growth factor ß-arrested epithelial cells. Mol Cell Biol 14: 3683-3694, 1994.
36. Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355, 1994.
37. Vogelstein B and Kinzler KW: X-rays strikep53 again. Nature 370: 174-175, 1994.
38. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP and Georgiev GP: A variation in the structure of the protein-coding region of the human p53 gene. Gene 70: 245-252, 1988.
39. Ahmad S, Mineta T, Martuza RL and Glazer RI: Antisense expression of protein kinase Cα inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 35: 904-909, 1994.
40. Ikemoto H, TaniE, Matsumoto T, Nakano A, Furuzama J: Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. J Neurosurg 84: 1008-1016, 1995.
41. Rinaudo MS, Su K, Falk LA, Haldar S and Mufson RA: Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood 86: 80-88, 1995.
42. Leszczynski D, Zhao Y, Luokkamaeki M and Foegh ML: Apoptosis of vascular smooth muscle cells-protein kinase C and oncoprotein bcl-2 are involved in regulation of apoptosis in non-transformed rat vascular smooth muscle cells. Am J Pathol 145: 1265-1270, 1994.
43. Mohammad RM, Diwakaran H, Maki A, Emara MA, Pettit GR, Redman B and Al-Katib A: Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 19: 667-673, 1995.
44. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T-T, Yu VL and Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43, 1995.
45. McConkey DJ, Hartzell P, Jondal M and Orrenius S: Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J Biol Chem 264: 13399-13402, 1989.
46. Rodriguez-Tarduchy G and Lopez-Rivas A: Phorbol esters inhibit apoptosis in IL-2 dependent T lymphocytes. Biochem Biophys Res Comm 164: 1069-1075, 1989.
47. Haimovitz-Friedman A, Balaban N, McLoughlin M, Ehleiter D, Michaeli J, Vlodavsky I and Fuks Z: Protein kinase C mediates basic fibroblasts growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 54: 2591-2597, 1994.
48. Jarvis WD, Turner AJ, Povirk LF, Traylor RS and Grant S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54: 1707-1714, 1994.
49. Bertrand R, Solary E, O'Connor P, Kohn KW and Pommier Y: Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res 217: 314-321, 1994.
50. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L and Moscat J: The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86: 777-786, 1996.
51. Ghosh S and Baltimore D: Activation in vitro of NF-κB by phosphorylation of its inhibitor IKB. Nature 344: 678-682, 1990.
52. Chang C-C, Zhang J, Lombardi L, Neri A and Dalla-Favera R: Mechanism of expression and role in transcriptional control of the proto-oncogene NF-κB-2/LYT-10. Oncogene 9: 923-933, 1994.
53. Beg AA and Baltimore D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274: 782-784, 1996.
54. Wang C-Y, Mayo MW and Baldwin AS: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274: 784-787, 1996.
55. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM: Suppression of TNF-α-induced apoptosis by NF-κB. Science 274: 787-789, 1996.
56. Seufert W, Futcher B and Jentsch S: Role of a ubiquitin-conjugated enzyme in degradation of S- and M-phase cyclins. Nature 373: 78-81, 1995.
57. Seufert W. Fulcher B and Jentsch S: Role of a ubiquitin-conjugated enzyme in degradation of S- and M-phase cyclins. Nature 373: 78-81, 1995.
58. Cdc2 activation required for apoptosis. Science 263: 1143-1145, 1994.
59. Shimizu T, O'Connor PM, Kohn KW and Pommier Y: Unscheduled activation of cyclin Bl/cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 55: 228-231, 1995.
60. Fotedar R, Flatt J, Gupta S, Margolis RL, Fitzgerald P, Messier H and Fotedar A: Activation-induced T-cell death is cell cycle dependent and regulated by cyclin B. Mol Cell Biol 15: 932-942, 1995.
61. cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1ß-converting enzyme- related proteases. Cancer Res 56: 4551-4555, 1996.
62. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR and Sikorska M: Apoptotic death in epithelial cells: cleavage of DNA of 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12: 3679-3684, 1993.
63. Ormerod MG, O'Neill CF, Robertson D and Harrap KR: Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp Cell Res 277; 231-237, 1994.
64. Watanabe H, Kanbe K, Shinozalci T, Hoshino H and Chigira M: Apoptosis of a fibrosarcoma induced by protein-free culture involves DNA cleavage to large fragments but not internucleosomal fragmentation. Int J Cancer 62: 191-198, 1995.
65. Filipski J, Leblanc J, Youdale T, Sikorska M and Walker PR: Periodicity of DNA folding in higher order chromatin structures. EMBO J 9: 1319-1327, 1990.
66. Savill J, Fadok V, Henson P and Haslett C: Phagocyte recognition of cells undergoing apoptosis. Immunol Today 14: 131-136, 1993.
67. Duvall E, Wyllie AH and Morris RG: Macrophage recognition of cells undergoing programmed cell death (apoptosis). Immunol 56: 351-358, 1985.